Emerging Company Profile
RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH
Powder aerosol formulations designed to avoid systemic effects that tripped up Novartis’ oral version
Aerovate’s powder aerosol formulations for rare pulmonary diseases are designed to avoid systemic effects.
Aug 13, 2020 | 10:54 PM GMT
Aerovate emerged from RA Capital’s incubator last